Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Mizutani

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2009
[Lung cancer]Hideaki Mizutani, Akihiko Gemma
Immunotherapy|April 22, 2020
Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case reportYasuhiro Kato, Yasutaka Watanabe, Yuki Yamane, et al.
Molecular Cancer Therapeutics|November 22, 2013
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cellsKazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, et al.
International Journal of Clinical Oncology|March 4, 2021
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutationsYasuhiro Kato, Gou Yamamoto, Yasutaka Watanabe, et al.
International Journal of Oncology|July 4, 2012
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cellsMengru Cao, Masahiro Seike, Chie Soeno, et al.
Oncology Letters|August 8, 2012
HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent mannerHideaki Mizutani, Tetsuya Okano, Yuji Minegishi, et al.
Future Oncology (London, England)|January 17, 2022
Uncommon <i>EGFR</i> mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, et al.
Japanese Journal of Clinical Oncology|May 11, 2016
Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional studyYukiko Miura, Yoshinobu Saito, Kenichiro Atsumi, et al.
Anticancer Research|October 13, 2012
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancerAkinobu Yoshimura, Rintaro Noro, Akihiko Miyanaga, et al.
Experimental and Therapeutic Medicine|November 9, 2012
Anticancer drug clustering based on proteomic profiles and a sensitivity database in a lung cancer cell line panelMitsunori Hino, Kuniko Matsuda, Akihiko Miyanaga, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2009
[Lung cancer]Hideaki Mizutani, Akihiko Gemma
Immunotherapy|April 22, 2020
Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case reportYasuhiro Kato, Yasutaka Watanabe, Yuki Yamane, et al.
Molecular Cancer Therapeutics|November 22, 2013
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cellsKazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, et al.
International Journal of Clinical Oncology|March 4, 2021
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutationsYasuhiro Kato, Gou Yamamoto, Yasutaka Watanabe, et al.
International Journal of Oncology|July 4, 2012
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cellsMengru Cao, Masahiro Seike, Chie Soeno, et al.
Oncology Letters|August 8, 2012
HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent mannerHideaki Mizutani, Tetsuya Okano, Yuji Minegishi, et al.
Future Oncology (London, England)|January 17, 2022
Uncommon <i>EGFR</i> mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, et al.
Japanese Journal of Clinical Oncology|May 11, 2016
Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional studyYukiko Miura, Yoshinobu Saito, Kenichiro Atsumi, et al.
Anticancer Research|October 13, 2012
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancerAkinobu Yoshimura, Rintaro Noro, Akihiko Miyanaga, et al.
Experimental and Therapeutic Medicine|November 9, 2012
Anticancer drug clustering based on proteomic profiles and a sensitivity database in a lung cancer cell line panelMitsunori Hino, Kuniko Matsuda, Akihiko Miyanaga, et al.
Pageof 3